Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Europe ends higher but New York struggles

Mon, 14th Nov 2022 16:55

(Alliance News) - European equities surrendered some afternoon gains but made a bright start to the week on Monday, shaking off hawkish noise from the US Federal Reserve, while investors waited with bated breath for the outcome of talks between the leaders of the world's two leading economies.

Presidents Joe Biden and Xi Jinping tried to take some heat out of their simmering superpower rivalry Monday, during a three-hour summit that found common ground on Ukraine but left little doubt that stark differences remain.

Biden emerged from the meeting proclaiming that there need not be a new Cold War, as both leaders spoke of the desire to prevent high tensions from spilling over into conflict.

Xi told Biden that the two countries "share more, not less, common interests", according to a Chinese account of the meeting, sounding more conciliatory than the last three pandemic-filled years without face-to-face presidential meetings would suggest.

The FTSE 100 index closed up 67.13 points, 0.9, at 7,385.17. The blue-chip index had been 1.3% higher earlier in the afternoon, but sentiment weakened slightly after a less-than-stellar start to the week for stocks in New York.

The FTSE 250 edged up just 6.04 points to 19,622.25. The AIM All-Share closed down 3.29 points, 0.4%, at 851.55.

The Cboe UK 100 ended up 0.9% at 739.02, the Cboe UK 250 closed down 0.1% at 16,921.03, and the Cboe Small Companies ended up 0.4% at 12,806.22.

In European equities on Monday, the CAC 40 in Paris ended up 0.2%, while the DAX 40 in Frankfurt ended up 0.6%.

"Fed speakers might have been out this weekend stressing the need to keep raising rates, but last week's CPI figure continues to provide the foundation for reviving bullish sentiment. European markets have put their best foot forward today," IG analyst Chris Beauchamp commented.

The dollar was largely supported on Monday, amid hawkish noise from the Federal Reserve.

Christopher Waller, a member of Federal Reserve Board of Governors, warned at a conference in Sydney that the endpoint to interest rate increases was likely "ways to go", downplaying cooler US consumer inflation data last week.

Reuters reported Waller said that while interest rates will rise in less sizeable increments, the Fed is not "softening" its inflation fight.

Markets should look at the "endpoint" of increases, not the pace of rate hikes.

The pound was quoted at USD1.1714 late Monday afternoon in London, down from USD1.1781 late Friday. The euro traded at USD1.0334, up from USD1.0326 on Friday. Against the yen, the dollar was quoted at JPY140.45, up from JPY139.07 on Friday.

The pound will be in focus this week due to the upcoming autumn budget.

UK Prime Minister Rishi Sunak has insisted that the budget's difficult decisions will have "fairness and compassion at their heart" after the chancellor warned everyone will be paying more tax.

The PM and Jeremy Hunt are considering allowing local authorities to impose larger rises in council tax next year to raise money for social care, among their tax-hiking measures.

IG's Beauchamp added: "Sterling-watchers have their work cut out for them this week. Normally unemployment data, inflation figures and retail sales would be enough to keep track of, but the fiscal statement this week adds spice to the pound's outlook. Barring some remarkable surprises, this week is not likely to be overflowing with good news for the UK economy."

Hunt is expected to make the support plan for energy bills less generous from April, instead switching to more targeted measures in order to save the Treasury billions, PA reported.

He is considering increasing the windfall tax on oil and gas giants from 25% to 35% while also expanding the levy to electricity generators.

Harbour Energy slid 9.4% in London on Monday, amid the windfall tax fears.

On the up, however, Informa surged 5.9%.

The London-based business publisher and events organiser upgraded its full-year outlook on the back of strong underlying revenue growth in the first 10 months of the year.

In the 10-months to October, it reported underlying revenue growth of 41% in its continuing business against the previous year. For 2021, Informa had posted an underlying revenue of GBP1.80 billion.

"Growth has been consistent across all specialist markets and all geographic regions where Covid restrictions have been removed and are fully open. In the US, customer demand has been particularly strong as business to business activity has returned at pace," Informa said.

Elsewhere in London, ME Group added 10% after it upgraded its full-year outlook thanks to a first-half performance which came in ahead of expectations.

The instant-service equipment firm noted a strong recovery across continental Europe and robust consumer demand for all its services, leading it to up its guidance for the year.

Revenue is now expected to be between GBP256 million and GBP262 million for the full-year ended October 31, up from GBP257 million previously. Earnings before interest, taxation, depreciation, and amortisation is now expected between GBP82 million and GBP85 million, up from between GBP79 million and GBP84 million previously.

On AIM, biopharmaceutical firm Hutchmed jumped 16% on positive trial results.

It said its gastric cancer treatment fruquintinib, when combined with chemotherapy paclitaxel, met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase-three study in 703 patients.

Progression-free survival is the length of time following treatment that a patient lives with the disease but does not see their condition worsen.

Stocks in New York were weaker at the time of the London equities close. The Dow Jones Industrial Average was down 0.1%, the S&P 500 was 0.3% lower and the Nasdaq Composite fell 0.9%.

Gold was priced at USD1,758.52 an ounce late Monday, down from USD1,763.60 late Friday. Brent oil fetched USD94.44 a barrel, down from USD96.32.

Tuesday's economic calendar has monetary policy minutes from the Reserve Bank of Australia posted overnight. There is also retail sales data from China before European markets open. There is unemployment data from the UK at 0700 GMT and the eurozone at 1000 GMT, before a US PPI reading at 1330 GMT.

The local corporate calendar has trading statements from defence firm BAE Systems and industrial turnaround specialist Melrose. Telecommunications company Vodafone posts half-year results, while Imperial Brands reports annual results.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 13:37

UK shareholder meetings calendar - next 7 days

Monday 6 May 
no events scheduled 
Tuesday 7 May 
Caledonia Mining Corp PLCAGM
CPPGroup PLCAGM
Just Group PLCAGM
Macfarlane Group PLC AGM
Plus500 LtdAGM
Supernova Digital Assets PLCAGM
Wednesday 8 May 
Airea PLCAGM
Antofagasta PLCAGM
Aston Martin Lagonda Global Holdings PLCAGM
Deltex Medical Group PLCAGM
Direct Line Insurance Group PLCAGM
Fidelity European Trust PLCAGM
Haleon PLCAGM
Jardine Matheson PLCAGM
JZ Capital Partners LtdEGM re investing in a secondary fund
Oscillate PLCAGM
Pershing Square Holdings LtdAGM
Rentokil Initial PLCAGM
WPP PLCAGM
Thursday 9 May 
Ascential PLCAGM
BAE Systems PLCAGM
Balfour Beatty PLCAGM
Barclays PLCAGM
CAB Payments Holdings PLCAGM
Catenai PLCGM re convertible loan note
Clarkson PLCAGM
FBD Holdings PLCAGM
Genel Energy plcAGM
Gym Group PLCAGM
Harbour Energy PLCAGM
Hiscox LtdAGM
IMI PLCAGM
Inchcape PLCAGM
Indivior PLCAGM
John Wood Group PLCAGM
Jupiter Fund Management PLCAGM
Logistics Development Group PLCAGM
Man Group PLCAGM
Morgan Advanced Materials PLCAGM
OSB Group PLCAGM
Public Policy Holding Co IncAGM
Rathbones Group PLCAGM
RM PLCAGM
Spire Healthcare Group PLCAGM
Synthomer PLCAGM
Uniphar PLCAGM
Friday 10 May 
Cairn Homes PLCAGM
Derwent London PLCAGM
Diversified Energy Co PLCAGM
Hutchmed China LtdAGM
Irish Residential Properties REIT PLCAGM
Kenmare Resources PLCAGM
Rightmove PLCAGM
Serinus Energy PLCAGM
Standard Chartered PLCAGM
Wheaton Precious Metals CorpAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
26 Apr 2024 16:09

Hutchmed notes CHMP's positive opinion for fruiquintinib approval

(Alliance News) - Hutchmed (China) Ltd on Friday said that its partner Takeda Pharmaceutical Co Ltd has been notified that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommends approval for fruquintinib.

Read more
5 Apr 2024 11:54

Hutchmed China to make several presentations at cancer research meeting

(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.

Read more
2 Apr 2024 12:11

Hutchmed endometrial cancer treatment gets priority review in China

(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday.

Read more
2 Apr 2024 10:32

Hutchmed endometrial cancer treatment application accepted for review

(Alliance News) - Hutchmed (China) Ltd on Tuesday jointly announced with Innovent Biologics that their new drug application for the combined fruquintinib and sintilimab treatment for endometrial cancer has been granted priority review by the China National Medical Products Administration.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
28 Mar 2024 13:02

Hutchmed cancer treatment indication accepted for review in China

(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).

Read more
28 Mar 2024 11:08

Hutchmed lung cancer treatment accepted for review in China

(Alliance News) - Hutchmed (China) Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration.

Read more
28 Mar 2024 08:08

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words from a US central banker.

Read more
22 Mar 2024 10:09

Hutchmed begins registration stage for sovleplenib phase 2/3 trial

(Alliance News) - Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm antibody autoimmune hemolytic anemia treatment.

Read more
28 Feb 2024 17:31

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Feb 2024 15:14

UK earnings, trading statements calendar - next 7 days

Thursday 22 February 
Anglo American PLCFull Year Results
Genus PLCHalf Year Results
Hargreaves Lansdown PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Indivior PLCFull Year Results
Jupiter Fund Management PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
ME Group International PLCFull Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
WPP PLCFull Year Results
Friday 23 February 
City of London Investment Group PLCHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
Standard Chartered PLCFull Year Results
Monday 26 February 
Base Resources LtdHalf Year Results
Bunzl PLCFull Year Results
EnSilica PLCHalf Year Results
Kosmos Energy LtdFull Year Results
Made Tech Group PLCHalf Year Results
Tristel PLCHalf Year Results
Tuesday 27 February 
abrdn Equity Income Trust PLCFull Year Results
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Kitwave Group PLCFull Year Results
McBride PLCHalf Year Results
PCI-PAL PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Synectics PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Wednesday 28 February 
AB Dynamics PLCTrading Statement
ASA International Group PLCTrading Statement
Aston Martin Lagonda Global Holdings PLCFull Year Results
Avingtrans PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Derwent London PLCFull Year Results
Glenveagh Properties PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Hutchmed China LtdFull Year Results
International Personal Finance PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Primary Health Properties PLCFull Year Results
Reckitt Benckiser Group PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
RHI Magnesita NVFull Year Results
St James's Place PLCFull Year Results
Taylor Wimpey PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
7 Feb 2024 09:50

Hutchmed hails fruquintinib trial results for gastric cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in overall survival for patients with gastric or gastroesophageal junction adenocarcinoma.

Read more
2 Feb 2024 09:52

Hutchmed says Inmagene exercises option to licence drug candidates

(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership.

Read more
2 Feb 2024 09:42

Hutchmed partner Inmagene exercises options over two drug candidates

(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.